OBESITY, PHYSICAL INACTIVITY AND SYMPTOMS AFTER OVARIAN CANCER TREATMENT: RESULTS FROM AN INTERNATIONAL INTERNET-BASED SURVEY
Kate Webber(Monash Health), Michael Friedländer(Prince of Wales Hospital), Ginna Witte, D. Sommeijer, Linda Mileshkin(Peter MacCallum Cancer Centre), Jessica N. McAlpine(University of British Columbia), Sarah P. Blagden(Churchill Hospital), T.J. Herzog, Robert L. Coleman(Texas Oncology), A. Silberman, Elisabeth Baugh
International Journal of Gynecological Cancer
October 1, 2015
Cited by 1
Related Papers
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
|The Lancet|2010|1.6k
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
|The Lancet|2007|1.5k
Rethinking ovarian cancer: recommendations for improving outcomes
|Nature reviews. Cancer|2011|1.5k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k